5,010 Biogen Inc. $BIIB Shares Sold by Nippon Life Global Investors Americas Inc.

Nippon Life Global Investors Americas Inc. lessened its stake in Biogen Inc. (NASDAQ:BIIB) by 3.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 132,210 shares of the biotechnology company’s stock after selling 5,010 shares during the period. Biogen accounts for approximately 1.2% of Nippon Life Global Investors Americas Inc.’s investment portfolio, making the stock its 27th largest holding. Nippon Life Global Investors Americas Inc. owned about 0.09% of Biogen worth $29,864,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of BIIB. BlackRock Inc. bought a new position in shares of Biogen during the 2nd quarter worth approximately $3,453,878,000. Primecap Management Co. CA acquired a new stake in Biogen in the second quarter valued at approximately $3,274,304,000. Wellington Management Group LLP boosted its stake in Biogen by 5.3% in the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after acquiring an additional 155,828 shares in the last quarter. Amundi grew its holdings in Biogen by 91.8% in the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock worth $327,727,000 after purchasing an additional 726,004 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in Biogen in the second quarter worth $322,640,000. 87.93% of the stock is currently owned by institutional investors.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wolfe Research raised Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a research report on Thursday, August 13th. JPMorgan Chase & Co. upgraded Biogen from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $210.00 to $300.00 in a research note on Monday, October 12th. Argus upgraded Biogen from a “hold” rating to a “buy” rating and set a $280.00 price target for the company in a research note on Thursday. Wedbush raised their price target on Biogen from $212.00 to $225.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Wall Street Zen upgraded Biogen from a “hold” rating to a “strong-buy” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Biogen has an average rating of “Moderate Buy” and an average target price of $251.00.

Biogen Price Performance

Shares of BIIB opened at $253.62 on Monday. The company’s fifty day moving average price is $227.08 and its 200-day moving average price is $201.04. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.37. The firm has a market capitalization of $37.49 billion, a PE ratio of 108.38, a price-to-earnings-growth ratio of 2.88 and a beta of 0.10. Biogen Inc. has a 1-year low of $146.52 and a 1-year high of $258.78.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The firm had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.63 billion. During the same period last year, the business posted $4.81 earnings per share. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. On average, equities research analysts predict that Biogen Inc. will post 12.44 EPS for the current year.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.